Max Nisen, Columnist

Valeant Is Pharma's Icarus

Its brazen denials of problems compound its strategic errors.

March 15, 2016 at 4:53 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

If there's been a defining characteristic of Valeant's attitude under CEO Mike Pearson, it's been hubris.

It has never presented itself as just another pharma company -- it was bravely redefining the industry, and its growth projections were stratospheric.